ethnic minority patients. 5, 6 After the 2004 box warning on antidepressants warned of an increased risk of suicidal ideation among young people, rates of antidepressant use significantly decreased for White youth, but slightly increased for Black and Latino youth, 7, 8 with high risk of abuse, addiction, or negative side effects.
Whether a racial/ethnic minority youth with depression is prescribed an antidepressant is likely to depend largely on the provider from whom they receive care. In studies of adult patients, providers that treat predominantly racial/ethnic minority patients are less likely to be influenced by new and emerging external scientific evidence compared to providers that treat predominantly White patients. 9, 10 Similarly, it has been found that clinicians in health care settings that serve diverse patients are less likely to employ evidence-based practices (EBPs). [11] [12] [13] As such, guidelines published by the FDA and other organizations may be less likely to influence treatment patterns of providers of racial/ethnic minority patients than providers of non-Latino White patients.
Ideally, providers and patients (and caregivers of youth patients) make decisions jointly about the treatment plan. 14 However, providers often use medical language that patients do not understand, and rarely ask patients about their preferences with respect to medications, therapies, and procedures. 15 Provider-patient communication is even worse among more marginalized patient groups such as racial/ethnic minorities. 15 Clinicians may be less likely to adequately communicate potential risks associated with a particular medical treatment to minority patients than White patients due to cultural and linguistic barriers.
Providers with specialty training in mental health (ie, psychologists, psychiatrists, social workers) are more likely to effectively receive, interpret, and disseminate information regarding EBPs than are pediatricians and other primary care providers (PCPs). This suggests that youth that receive mental health treatment from only a PCP (approximately 1/3 of all youth receiving mental health treatment 16 ) may be at a greater risk for missing key risk information. This may be of greater concern for racial/ethnic minority youth given that they are more likely than Whites to seek mental health care with PCPs than specialists. 17, 18 Furthermore, racial/ethnic disparities in diagnosis and treatment (through counseling and/or medication) of anxiety and depression are greater in primary care than in psychiatric service settings. 19 The reduced access to and utilization of specialty mental health care providers for racial/ethnic minority youth may thus present additional obstacles to effective dissemination of risk information to minority patients and their caregivers.
At the patient level, there are several reasons why racial/ethnic minority youth patients and their caregivers may be less likely than White youth patients and their caregivers to respond to an FDA risk warning.
Firstly, racial/ethnic minorities tend to receive health information from different sources than Whites and are less likely to trust the information that they receive. 20 While there was significant coverage of the box warning in news outlets and the popular press, 21 racial/ethnic minority families may have been less exposed to this coverage. Secondly, many consumers avoided depression treatment altogether after the box warning. [22] [23] [24] Native American, and multi racial youth due to small sample sizes.
Claims were aggregated to the patient-month unit of analysis; each observation contains antidepressant data for a given month for a specific patient. For each patient-month, we assigned the patient to the provider that he/she saw for the greatest percentage of their outpatient visits in that calendar year. In the case of ties, one of the tied providers was randomly chosen. If there were no visits during the year or there was no available provider identifier, then the patient data were not used for that year. The list of antidepressants was determined using Multum medication classification codes.
This data structure allows for multilevel modeling, which can account for the non independence of multiple months of data from the same individual. 28 Further, this modeling strategy allows for investigation of provider-level differences that are not possible in the unilevel difference-in-differences and interrupted time series models used in prior box warning studies. In particular, it allows testing of whether data from multiple individuals seeing the same provider are non independent. A further benefit of multilevel models is that they use data from all available individuals and providers, even those with missing data in some of the time periods.
| Model
We implemented a multilevel linear probability model to examine the differential impact by race/ethnicity of the box warning (equa- Y tij is the dichotomous dependent variable, coded as 1 if there is a filled prescription for an antidepressant for individual patient i from provider j at month t, and 0 otherwise. Months is a counter variable that equals 1 for the first month of the study period and increases by 1 for every month thereafter, Post-BW is a 0/1 indicator of whether or not a given month was before or after the box warning came out, and MonthsPost-BW is a counter variable that equals 1 for the first month after the box warning came out and increases by 1 for every month thereafter.
Race/ethnicity (race) was determined using categories of non-Latino White ("White"), non-Latino Black or African American ("Black"), and
Latino or Hispanic ("Latino"). The coefficients on the race ij variables in level 2 represent interactions between race ij and time variables.
Covariances between random effects were assumed to be zero.
In the third analysis of interest, in order to better understand provider-level variance, we tested the significance of observed provider-level covariates, estimating a new multilevel model (equations 2a-i). Specifically, we compared how the diffusion of the box warning across providers varied by the racial/ethnic makeup of their patient panels by estimating the following model, which simplified the patient-level equations 1b-e in order to focus on the provider level without excess interaction terms (equations 2f-i):
Level 2 (patient): were greater or less among providers who had >2/3 racial/ethnic minority patients, as compared to providers who had <1/3 racial/ethnic minority patients. All models were estimated using the STATA 14 software package (StataCorp LLC, College Station, TX, USA).
| RE SULTS
We first describe, by race/ethnicity, the gender, Medicaid eligibility type, probability of any antidepressant fill, and age as of January 2002 or a patient's first appearance in the MAX data ( Table 1) .
As has been found in previous studies, there is a decline in antidepressant use across racial/ethnic groups. We identified sig- (Table 2 ; only Black interactions were reported for simplicity).
The sequential likelihood ratio tests demonstrate that there continues to be significant improvement in model fit and thereby significant variation by provider underlying the differential box warning effect on Blacks over time.
Results in the third main analysis show that providers with >2/3 minority patients prescribed antidepressants at a lower rate than providers whose share of minority patients was less than 1/3 (Table 3) .
Consistent with our hypothesis, the interaction coefficients of the post-box warning slope change and "provider with >2/3 minority patients" were significantly positive, indicating that there were smaller rates of decline in antidepressant prescribing among providers with >2/3 minority patients after the box warning compared to providers with panels that had less than 1/3 minority patients.
| D ISCUSS I ON
This study is the first of which we are aware to assess provider-and TA B L E 2 Intraclass correlation for provider random intercepts model and likelihood ratio tests assessing the significance of adding provider-level random effects on each of the time and time*race/ethnicity covariates level, after conditioning on race, time, and race-time interactions;
(b) significant unexplained provider-level variation related to the differential patterns in antidepressant usage by patient race/ethnicity both before and after the box warning (tested by sequential LR tests); and (c) antidepressant prescribing rates of providers with a large proportion of minority patients declined more slowly than the rates of providers with a smaller proportion of minority patients.
The unexplained provider-level variation in our first model suggests that providers significantly affected the changes in antidepressant use after the box warning; however, several assumptions are required to equate provider variation with provider influence, including the critical assumption that physicians that had an effect on the shift were also responsible for changes in overall trends in antidepressant use. Alternatively, the strong influence by providers on the shift in antidepressant use could be due to the fact that patients of each provider were clustered among a small group of communities or neighborhoods with distinct attitudes concerning antidepressant use. In that scenario, the uniqueness of the composition of patients within providers' panels, as opposed to the influence of the provider on those patients, explains our findings. We know of no prior studies describing significant regional or neighborhood differences among racial/ethnic minority patients in medication use, but we cannot rule out this possibility. that of prior studies finding that differences in quality of care between racial/ethnic minority and White adult patients are to a large extent due to the fact that minority patients are treated by different groups of physicians 11 and in different inpatient hospital settings. 29 One implication is that policy makers concerned with equitable diffusion of innovation (or "exnovation" 30 in the case of scaling back existing practices because of risk warnings)
should consider interventions that intentionally reach out to providers that predominantly treat racial/ethnic minority patients.
Furthermore, this provides evidence that de facto segregation across hospitals (due in part to differential physician referral practices and historical catchment areas that mirror residential segregation) 31 ,32 may extend to outpatient pediatric settings where psychotropic medications are prescribed. The significant underlying provider-level variation in prescribing patterns both before and after the box warning suggests that policies seeking equity in diffusion of innovation and risk warnings will need to target resources toward the outpatient facilities and community health centers that predominantly treat youth of color.
The fact that there also remains significant individual-level variation in prescribing patterns suggests that there should be policies put into place that reduce potentially biased treatment patterns within these facilities and increase direct outreach and education to patients and their caregivers on the costs and benefits of new and high-risk treatments. Future studies may benefit from exploring variation by provider type (eg, primary care physicians, psychiatrists, nurse practitioners); unfortunately, the MAX data used in this study do not contain National Physician Identification
Numbers for the majority of the claims, making it impossible to link our analytical dataset with other datasets with physician specialty information. 33 The delicate balance of risks and benefits of antidepressants (and other psychotropic medications) complicate the implications from our findings. Although there is a robust body of evidence demonstrating the effectiveness of psychotropic medication in the treatment of mood, psychotic, anxiety, developmental, and behavioral disorders, 34 psychotropic medications can cause severe side effects, particularly SSRIs prescribed to young patients. 35, 36 Therefore, the net clinical effect of reduced use of these medications (and a reduction in racial/ethnic differences in antidepressant use) in response to the box warning is not obvious, especially when baseline utilization levels vary across groups.
That patients and their families do contribute significantly to decision making is notable and perhaps attributable to the fact that patients and families were very likely exposed to the significant coverage related to the box warning in news outlets and in the popular press. 21 We offer evidence that providers contribute to larger shifts in prescribing antidepressants for Whites as compared to Black and Latino patients, in relative and absolute terms, as differences in the speed of risk diffusion varied by the racial/ethnic composition of the patient panel of providers. The reaction to the box warning was slower among providers with more than 2/3 minority patients compared with providers with panels of predominantly White patients. This result is consistent with prior studies showing that providers of racial/ethnic minority patients are less likely to be influenced by the research findings of the FDA and other organizations than providers of White patients. 37 These findings also echo prior studies in the adult patient literature demonstrating that providers serving predominantly minority patients provide potentially lower quality of care than providers serving predominantly White patients. [11] [12] [13] Additionally, the family and individual preferences of racial/ethnic minorities to prefer talk therapy over antidepressants, 17 poorer communication between clinicians and their racial/ethnic minority patients, and statistical discrimination toward minority patients 38, 39 may play important roles in the differential influence of providers.
In conclusion, this study identified that the reduction in racial/ ethnic differences in antidepressant use after the box warning (caused by the decline among White youth and steady rates among Blacks and Latinos) was in large part explained by the fact that racial/ethnic minority youth largely seek care from a different subset of providers than White youth and that minority-serving providers reacted differently to the box warning. As rates of psychotropic medication use in youth continue to climb in the United States, 40 information about the long-term risks of these medications has emerged eg, 41, 42 and will continue to challenge decision making for providers, youth living with mental illness, and their caregivers.
Going forward, policy makers and prescribers should pay close attention to how these risk warnings are disseminated and the differential practice patterns of providers of youth of color, and target resources and provider education to lower the risk of adverse health outcomes faced by these vulnerable patient populations. 
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* We choose to use difference as opposed to disparity when discussing racial/ethnic differences in antidepressant use in order to remain agnostic about the value of an increase or decrease in antidepressant use. While there is some debate over the risks and benefits of the box warning and changes in antidepressant use, we are concerned in this study with the influence of the warning on provider and patient behavior as opposed to assessing whether the warning was beneficial or not.
